Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × elesclomol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Melanoma 1

Interventions

Paclitaxel 20 Dexamethasone 16 Bevacizumab 16 Gemcitabine 15 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Leucovorin 10 Fluorouracil 10 Pemetrexed 9 Epoetin Alfa 9 Cisplatin 9 venetoclax 8 pembrolizumab 8 Prednisone 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 atezolizumab 7 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00522834 2014-03-04

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 3 Terminated

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡